Multiple antidepressant potential modes of action of curcumin: A review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects

Journal of Psychopharmacology

Volumn 26, Issue 12, 2012, Pages 1512-1524

  Lopresti, Adrian L ^a   Hood, Sean D ^b   Drummond, Peter D ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Curcumin; depression; herbal treatment; inflammation; natural antidepressant; turmeric

Indexed keywords

AMITRIPTYLINE; BCM 95; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DOPAMINE; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; MERIVA; NEUROTRANSMITTER; NITRIC OXIDE; NORADRENALIN; PLACEBO; SEROTONIN; SERTRALINE; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; DEPRESSION; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; INTESTINE HYPERPERMEABILITY; INTESTINE MUCOSA PERMEABILITY; MAJOR DEPRESSION; MONOAMINERGIC ACTIVITY; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PRIORITY JOURNAL; REMISSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; IMMUNOLOGIC FACTORS; NEUROPROTECTIVE AGENTS; SEROTONIN;

EID: 84870421027     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112458732     Document Type: Article

References (186)

1. Abbasi SH, Hosseini F, Modabbernia A, et al. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord. 2012 2012 ;:
2. Abdipranoto A, Wu S, Stayte S, et al. The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets. 2008 ; 7: 187-210
3. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol Sci. 2009 ; 30: 85-94
4. Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact. 2008 ; 174: 27-37
5. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009 ; 26: 607-611
6. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J. 2001 ; 357: 593-615
7. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: Problems and promises. Mol Pharm. 2007 ; 4: 807-818
8. Antony B, Merina B, Iyer S, et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008 ; 70: 445-450
9. Arora V, Kuhad A, Tiwari V, et al. Curcumin ameliorates reserpine-induced pain-depression dyad: Behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology. 2011 ; 36: 1570-1581
10. Baran H, Staniek K, Kepplinger B, et al. Kynurenines and the respiratory parameters on rat heart mitochondria. Life Sci. 2003 ; 72: 1103-1115
11. Basnet P, Skalko-Basnet N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011 ; 16: 4567-4598
12. Basu GD, Tinder TL, Bradley JM, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: Role of IDO. J Immunol. 2006 ; 177: 2391-2402
13. Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010 ; 15: 337-344
14. Bereswill S, Munoz M, Fischer A, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One. 2010 ; 5: e15099
15. Bhatia N, Jaggi AS, Singh N, et al. Adaptogenic potential of curcumin in experimental chronic stress and chronic unpredictable stress-induced memory deficits and alterations in functional homeostasis. J Nat Med. 2011 ; 65: 532-543
16. Bhutani MK, Bishnoi M, Kulkarni SK. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav. 2009 ; 92: 39-43
17. Bishnoi M, Chopra K, Kulkarni SK. Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav. 2008 ; 88: 511-522
18. Bishnoi M, Chopra K, Rongzhu L, et al. Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: Cellular and neurochemical evidence. Neurotox Res. 2011 ; 20: 215-225
19. Braidy N, Grant R, Adams S, et al. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J. 2010 ; 277: 368-382
20. Braidy N, Guillemin GJ, Grant R. Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011 ; 4: 29-37
21. Calabrese JR, Skwerer RG, Barna B, et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 1986 ; 17: 41-47
22. Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology (Berl). 2011 ; 213: 265-287
23. Cesario A, Rocca B, Rutella S. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem. 2011 ; 18: 2263-2271
24. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012 2012 ;:
25. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: Disease and healthy States. Int J Tryptophan Res. 2009 ; 2: 1-19
26. Chen Y, Jiang T, Chen P, et al. Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells. Psychiatry Res. 2011 ; 188: 224-230
27. Chimakurthy J, Talasila M. Effects of curcumin on pentylenetetrazole- induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci. 2010 ; 3: 239-244
28. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005 ; 29: 571-625
29. Cumurcu BE, Ozyurt H, Etikan I, et al. Total antioxidant capacity and total oxidant status in patients with major depression: Impact of antidepressant treatment. Psychiatry Clin Neurosci. 2009 ; 63: 639-645
30. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011 ; 74: 664-669
31. Dantzer R, O'Connor JC, Lawson MA, et al. Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology. 2011 ; 36: 426-436
32. Dhir A, Kulkarni SK. Nitric oxide and major depression. Nitric Oxide. 2011 ; 24: 125-131
33. Dobos N, de Vries EF, Kema IP, et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis. 2012 ; 28: 905-915
34. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010 ; 67: 446-457
35. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: Stress and depression. Dialogues Clin Neurosci. 2009 ; 11: 239-255
36. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006 ; 59: 1116-1127
37. Dunn AJ. Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res. 2006 ; 6: 52-68
38. Eyre H, Baune BT. Neuroplastic changes in depression: A role for the immune system. Psychoneuroendocrinology. 2012 ; 37: 1397-1416
39. Fasano A, Shea-Donohue T. Mechanisms of disease: The role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 ; 2: 416-422
40. Fattal O, Link J, Quinn K, et al. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr. 2007 ; 12: 429-438
41. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'- deoxyguanosine in clinical depression. Psychosom Med. 2006 ; 68: 1-7
42. Fu X, Zunich SM, O'Connor JC, et al. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation. 2010 ; 7: 43
43. Galecki P, Galecka E, Maes M, et al. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord. 2012 ; 138: 360-366
44. Gao SF, Bao AM. Corticotropin-releasing hormone, glutamate, and gamma-aminobutyric acid in depression. Neuroscientist. 2011 ; 17: 124-144
45. Gardner A, Boles RG. Mitochondrial energy depletion in depression with somatization. Psychother Psychosom. 2008a ; 77: 127-129
46. Gardner A, Boles RG. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med. 2008b ; 2: 7
47. Gardner A, Boles RG. Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 730-743
48. Gardner A, Johansson A, Wibom R, et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord. 2003 ; 76: 55-68
49. Gilhotra N, Dhingra D. GABAergic and nitriergic modulation by curcumin for its antianxiety-like activity in mice. Brain Res. 2010 ; 1352: 167-175
50. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs. low CRH/NE states. Mol Psychiatry. 2002 ; 7: 254-275
51. Government Medical College, Bhavnagar; Health and Family Welfare Department, Government of Gujarat, India; Arjuna Natural Extracts Ltd, Kerala, India (2012). A randomized, active controlled, open label, parallel group study to compare the efficacy of extract of curcuma longa (turmeric) with fluoxetine and to study its effect as an add on therapy to fluoxetine in patients of depression. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine, US. Available at: http://clinicaltrials.gov/ct2/show/NCT01022632. ClinicalTrials.gov NLM Identifier: NCT01022632 (accessed 17 August 2012).
52. Greco T, Fiskum G. Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis. 2010 ; 20: S427-437
53. Gupta SC, Patchva S, Koh W, et al. Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin Exper Pharmacol Physiol. 2012 ; 39: 283-299
54. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology. 2011 ; 36: 2452-2459
55. Henry CJ, Huang Y, Wynne A, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008 ; 5: 15
56. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis. 2004 ; 25: 1671-1679
57. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med. 2009 ; 71: 171-186
58. Huang WT, Niu KC, Chang CK, et al. Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur J Pharmacol. 2008 ; 593: 105-111
59. Huang Z, Zhong XM, Li ZY, et al. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett. 2011 ; 493: 145-148
60. Jeong YI, Kim SW, Jung ID, et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem. 2009 ; 284: 3700-3708
61. Jiang H, Tian X, Guo Y, et al. Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biol Pharm Bull. 2011 ; 34: 1194-1197
62. Joca SR, Guimaraes FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl). 2006 ; 185: 298-305
63. Jung ID, Jeong YI, Lee CM, et al. COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells. Int Immunopharmacol. 2010 ; 10: 760-768
64. Jung KK, Lee HS, Cho JY, et al. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci. 2006 ; 79: 2022-2031
65. Kanakasabai S, Casalini E, Walline CC, et al. Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J Nutr Biochem. 2012 2012 ;:
66. Karatepe O, Acet E, Battal M, et al. Effects of glutamine and curcumin on bacterial translocation in jaundiced rats. World J Gastroenterol. 2010 ; 16: 4313-4320
67. Karolewicz B, Szebeni K, Stockmeier CA, et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem. 2004 ; 91: 1057-1066
68. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol. 2011 ; 45: 365-370
69. Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: The potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003 ; 8: 365-370
70. Kincses ZT, Toldi J, Vecsei L. Kynurenines, neurodegeneration and Alzheimer's disease. J Cell Mol Med. 2010 ; 14: 2045-2054
71. Koene S, Kozicz TL, Rodenburg RJ, et al. Major depression in adolescent children consecutively diagnosed with mitochondrial disorder. J Affect Disord. 2009 ; 114: 327-332
72. Kulkarni S, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. ScientificWorldJournal. 2009 ; 9: 1233-1241
73. Kulkarni SK, Dhir A. An overview of curcumin in neurological disorders. Indian J Pharm Sci. 2010 ; 72: 149-154
74. Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: Involvement of serotonin and dopamine system. Psychopharmacology (Berl). 2008 ; 201: 435-442
75. Kumar A, Singh A. Possible nitric oxide modulation in protective effect of (Curcuma longa, Zingiberaceae) against sleep deprivation-induced behavioral alterations and oxidative damage in mice. Phytomedicine. 2008 ; 15: 577-586
76. Lee BH, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010 ; 7: 231-235
77. Lee BH, Lee SW, Yoon D, et al. Increased plasma nitric oxide metabolites in suicide attempters. Neuropsychobiology. 2006 ; 53: 127-132
78. Lee KH, Abas F, Alitheen NB, et al. A curcumin derivative, 2,6-bis(2,5-dimethoxybenzylidene)-cyclohexanone (BDMC33) attenuates prostaglandin E2 synthesis via selective suppression of cyclooxygenase-2 in IFN-g/LPS-stimulated macrophages. Molecules. 2011 ; 16: 9728-9738
79. Lee SY, Choi HK, Lee KJ, et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother. 2009 ; 32: 22-28
80. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012 ; 36: 764-785
81. Li YC, Wang FM, Pan Y, et al. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33: 435-449
82. Lin TY, Lu CW, Wang CC, et al. Curcumin inhibits glutamate release in nerve terminals from rat prefrontal cortex: possible relevance to its antidepressant mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1785-1793
83. Linnoila M, Whorton AR, Rubinow DR, et al. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry. 1983 ; 40: 405-406
84. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J Affect Disord. 2012 ; 139: 230-239
85. Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: State of the art. Acta Anaesthesiol Belg. 2011 ; 62: 47-58
86. McBride HM, Neuspiel M, Wasiak S. Mitochondria: More than just a powerhouse. Curr Biol. 2006 ; 6: R551 - R560
87. McEntee WJ, Crook TH. Glutamate: Its role in learning, memory, and the aging brain. Psychopharmacology (Berl). 1993 ; 111: 391-401
88. McLeod TM, Lopez-Figueroa AL, Lopez-Figueroa MO. Nitric oxide, stress, and depression. Psychopharmacol Bull. 2001 ; 35: 24-41
89. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: A literature review. CNS Spectr. 2008 ; 13: 501-510
90. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 664-675
91. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res. 2012 ; 196: 243-249
92. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012a ; 10: 66
93. Maes M, De Vos N, Pioli R, et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord. 2000 ; 58: 241-246
94. Maes M, Galecki P, Chang YS, et al. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 2011a ; 35: 676-692
95. Maes M, Galecki P, Verkerk R, et al. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett. 2011b ; 32: 264-273
96. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008a ; 29: 117-124
97. Maes M, Kubera M, Leunis JC, et al. Increased IgA and IgM responses against gut commensals in chronic depression: Further evidence for increased bacterial translocation or leaky gut. J Affect Disord. 2012b ; 141: 55-62
98. Maes M, Leonard BE, Myint AM, et al. The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011c ; 35: 702-721
99. Maes M, Mihaylova I, Kubera M, et al. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett. 2008b ; 29: 313-319
100. Maes M, Mihaylova I, Kubera M, et al. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett. 2009a ; 30: 715-722
101. Maes M, Mihaylova I, Kubera M, et al. Lower plasma coenzyme Q10 in depression: A marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett. 2009b ; 30: 462-469
102. Maes M, Mihaylova I, Kubera M, et al. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: New pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord. 2011d ; 135: 414-418
103. Maes M, Mihaylova I, Kubera M, et al. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/ chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett. 2011e ; 32: 133-140
104. Maes M, Mihaylova I, Ruyter MD, et al. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): Relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett. 2007 ; 28: 826-831
105. Maes M, Scharpe S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res. 1994 ; 54: 143-160
106. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009c ; 24: 27-53
107. Maes M, Zdenek F, Medina M, et al. New drug targets in depression: Inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates - Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012c ; 20: 127-150
108. Magalhaes PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr. 2011 ; 33: 374-378
109. Maletic V, Robinson M, Oakes T, et al. Neurobiology of depression: An integrated view of key findings. Int J Clin Pract. 2007 ; 61: 2030-2040
110. Manikandan R, Beulaja M, Thiagarajan R, et al. Ameliorative effects of curcumin against renal injuries mediated by inducible nitric oxide synthase and nuclear factor kappa B during gentamicin-induced toxicity in Wistar rats. Eur J Pharmacol. 2011 ; 670: 578-585
111. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001 ; 7: 541-547
112. Martinowich K, Lu B. Interaction between BDNF and serotonin: Role in mood disorders. Neuropsychopharmacology. 2008 ; 33: 73-83
113. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007 ; 10: 1089-1093
114. Mathew SJ, Shah A, Lapidus K, et al. Ketamine for treatment-resistant unipolar depression: Current evidence. CNS Drugs. 2012 ; 26: 189-204
115. Matthes S, Mosienko V, Bashammakh S, et al. Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology. 2010 ; 85: 95-109
116. MD Anderson Cancer Center (2012). Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available at: http://clinicaltrials.gov/ ct2/show/NCT00094445. ClinicalTrials.gov NLM Identifier: NCT00094445.
117. Mendlewicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. Int Clin Psychopharmacol. 2006 ; 21: 227-231
118. Menon VP, Sudheer AR The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Aggarwal BB Surh YJ Shishodia S, ed. New York: Springer ; 2007 :
119. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006 ; 63: 1209-1216
120. Miller AL. The pathogenesis, clinical implications, and treatment of intestinal hyperpermeability. Alt Med Rev. 1997 ; 2: 330-345
121. Moriyuki K, Sekiguchi F, Matsubara K, et al. Curcumin inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-κB in human lung epithelial cells. J Pharmacol Sci. 2010 ; 114: 225-229
122. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des. 2008 ; 14: 1452-1465
123. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006 ; 11: 680-684
124. Myint AM. Kynurenines: From the perspective of major psychiatric disorders. FEBS J. 2012 ; 279: 1375-1385
125. Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007 ; 98: 143-151
126. Myint AM, Leonard BE, Steinbusch HW, et al. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord. 2005 ; 88: 167-173
127. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011 ; 10: 209-219
128. Naik SR, Thakare VN, Patil SR. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property. Exper Toxicol Pathol. 2011 ; 63: 419-431
129. Nemeroff CB, Krishnan KR, Reed D, et al. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry. 1992 ; 49: 384-387
130. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008 ; 11: 851-876
131. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009 ; 14: 511-522
132. Ohishi K, Ueno R, Nishino S, et al. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry. 1988 ; 23: 326-334
133. Owen AJ, Batterham MJ, Probst YC, et al. Low plasma vitamin E levels in major depression: Diet or disease?. Eur J Clin Nutr. 2005 ; 59: 304-306
134. Ozcan ME, Gulec M, Ozerol E, et al. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004 ; 19: 89-95
135. Pariante CM, Lightman SL. The HPA axis in major depression: Classical theories and new developments. Trends Neurosci. 2008 ; 31: 464-468
136. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology (Berl). 2005 ; 177: 245-255
137. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exper Mol Pathol. 2007 ; 83: 84-92
138. Pinto VL, Brunini TM, Ferraz MR, et al. Depression and cardiovascular disease: Role of nitric oxide. Cardiovasc Hematol Agents Med Chem. 2008 ; 6: 142-149
139. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999 ; 18: 6013-6020
140. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007 ; 55: 453-462
141. Rai B, Kaur J, Jacobs R, et al. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci. 2010 ; 52: 251-256
142. Raison CL, Miller AH. Is depression an inflammatory disorder?. Curr Psychiatry Rep. 2011 ; 13: 467-475
143. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 2006 ; 27: 24-31
144. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: Relationship to CNS immune responses and depression. Mol Psychiatry. 2010 ; 15: 393-403
145. Rezin GT, Amboni G, Zugno AI, et al. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 2009 ; 34: 1021-1029
146. Sanmukhani J, Anovadiya A, Tripathi CB. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: An acute and chronic study. Acta Pol Pharm. 2011 ; 68: 769-775
147. Sarandol A, Sarandol E, Eker SS, et al. Major depressive disorder is accompanied with oxidative stress: Short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol. 2007 ; 22: 67-73
148. Scapagnini G, Vasto S, Abraham NG, et al. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol. 2011 ; 44: 192-201
149. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry. 2008 ; 64: 527-532
150. Shao L, Martin MV, Watson SJ, et al. Mitochondrial involvement in psychiatric disorders. Ann Med. 2008 ; 40: 281-295
151. Shih CA, Lin JK. Inhibition of 8-hydroxydeoxyguanosine formation by curcumin in mouse fibroblast cells. Carcinogenesis. 1993 ; 14: 709-712
152. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998 ; 64: 353-356
153. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev. 2005 ; 29: 627-647
154. Sood PK, Nahar U, Nehru B. Curcumin attenuates aluminum-induced oxidative stress and mitochondrial dysfunction in rat brain. Neurotox Res. 2011 ; 20: 351-361
155. Srivastava RM, Singh S, Dubey SK, et al. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol. 2011 ; 11: 331-341
156. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?. J Neuroinflammation. 2011 ; 8: 94
157. Steru L, Chermat R, Thierry B, et al. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985 ; 85: 367-370
158. Stone TW, Forrest CM, Darlington LG. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012 ; 279: 1386-1397
159. Suzuki E, Yagi G, Nakaki T, et al. Elevated plasma nitrate levels in depressive states. J Affect Disord. 2001 ; 63: 221-224
160. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 693-701
161. Tocharus J, Jamsuwan S, Tocharus C, et al. Curcuminoid analogs inhibit nitric oxide production from LPS-activated microglial cells. J Nat Med. 2012 ; 66: 400-405
162. Toker L, Amar S, Bersudsky Y, et al. The biology of tryptophan depletion and mood disorders. Isr J Psychiatry Relat Sci. 2010 ; 47: 46-55
163. University of California, Los Angeles (2012). Curcumin in rheumatoid arthritis - a cross-over pilot study. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine, US. Available from: http://clinicaltrials.gov/ct2/show/NCT00752154. ClinicalTrials.gov NLM Identifier: NCT00752154 (accessed 17 August 2012).
164. Usharani P, Mateen AA, Naidu MUR, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus. Drugs R D. 2008 ; 9: 243-205
165. Wang R, Xu Y, Wu HL, et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol. 2008 ; 578: 43-50
166. Wang Y, Cui XL, Liu YF, et al. LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1831-1835
167. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: A comprehensive review of findings. Curr Psychiatry Rep. 2007 ; 9: 449-459
168. Wei QY, Chen WF, Zhou B, et al. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta. 2006 ; 1760: 70-77
169. Wei YC, Zhou FL, He DL, et al. The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma. J Psychosom Res. 2009 ; 66: 259-266
170. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005 ; 10: 538-544
171. World Health Organisation (2008) The global burden of disease: 2004 update. Available at: http://www.who.int/healthinfo/global/burden/disease/2004/ report/update/en/index.html (accessed
172. Xia X, Cheng G, Pan Y, et al. Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test. J Ethnopharmacol. 2007 ; 110: 356-363
173. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol. 2009 ; 9: 575-581
174. Xu Y, Ku B, Cui L, et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res. 2007 ; 1162: 9-18
175. Xu Y, Ku BS, Yao HY, et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav. 2005a ; 82: 200-206
176. Xu Y, Ku BS, Yao HY, et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol. 2005b ; 518: 40-46
177. Xu Y, Li S, Vernon MM, et al. Curcumin prevents corticosterone-induced neurotoxicity and abnormalities of neuroplasticity via 5-HT receptor pathway. J Neurochem. 2011 ; 118: 784-795
178. Yang C, Zhang X, Fan H, et al. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 2009 ; 1282: 133-141
179. Yaron I, Shirazi I, Judovich R, et al. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 1999 ; 42: 2561-2568
180. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996 ; 711: 163-174
181. Yirmiya R, Pollak Y, Barak O, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology. 2001 ; 24: 531-544
182. Zádori D, Klivényi P, Vámos E, et al. Kynurenines in chronic neurodegenerative disorders: Future therapeutic strategies. J Neural Transm. 2009 ; 116: 1403-1409
183. Zhang KS, Li GC, He YW, et al. Curcumin inhibiting the expression of indoleamine 2,3-dioxygenase induced by IFN-gamma in cancer cells. Zhong Yao Cai. 2008 ; 31: 1207-1211
184. Zhang M, Deng CS, Zheng JJ, et al. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin. 2006 ; 27: 1071-1077
185. Zhu YG, Chen XC, Chen ZZ, et al. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol Sin. 2004 ; 25: 1606-1612
186. Zunszain PA, Anacker C, Cattaneo A, et al. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 722-729